Overview

Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function

Status:
Completed

Trial end date:
2009-08-01

Target enrollment:

Participant gender:

Summary

1. To compare the pharmacokinetics of Dimebon in subjects with mild and moderate hepatic impairment to subjects with normal hepatic function. 2. To assess the safety and tolerability of Dimebon in subjects with hepatic impairment and subjects with normal hepatic function. 3. To explore the pharmacokinetics of Dimebon in subjects with severely-impaired hepatic function.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Collaborator:

Medivation, Inc.